Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MTJCT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Trastuzumab-PNU-159682 Antibody-Drug Conjugate
|
|||||
| Synonyms |
Trastuzumab-PNU-159682 antibody-drug conjugate (Genentech)
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc.; Roche Holding AG
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
PNU-159682
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.